medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2020, Number 2

<< Back Next >>

Neumol Cir Torax 2020; 79 (2)

Recommendations from Experts for Asthma Awareness in Mexico

Cuevas-Schacht F, Gómez-Vera J, López-Estrada EC, Magdaleno-Maldonado G, Maldonado-Hernández JG, Moncayo-Coello CV, Rojo-Gutiérrez MI, Ochoa-Vázquez D, Pech-Alonso B, Llópiz-Avilés MT, Boy-Ojeda AE, Lezama-Armenta AA

Language: Spanish
References: 8
Page: 116-120
PDF size: 218.12 Kb.


ABSTRACT

Introduction: The 2019 GINA strategy report presents the most relevant changes in asthma management in the last 30 years. Objective: The purpose of this article is to disseminate the changes in GINA 2019 regarding the treatment of mild asthma, and to express the position and recommendations from the members of the experts for awareness of asthma in Mexico. Methodology: A group of opinion leaders and asthma experts in Mexico was brought together to discuss the studies and evidence that support the changes in GINA 2019. Results: Positions and strategies were defined to address the different challenges posed by these changes. Conclusions: The recommendation is that every asthma patient should receive anti-inflammatory treatment. One strategy in patients with intermittent symptoms is to use a low-dose inhaled corticosteroid/formoterol as a preferred reliever, and daily low dose ICS/formoterol both as control and rescue (as needed) treatment for patients with persistent symptoms. The results of the studies and their impact on clinical practice are promising.


REFERENCES

  1. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention (for adults and children older than 5 years) [accesado: 19 de julio de 2019]. Disponible en: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf

  2. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. (SYGMA 1). N Engl J Med 2018;378(20):1865-1876. https://doi.org/10.1056/nejmoa1715274

  3. Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. (SYGMA 2). N Engl J Med 2018;378(20):1877-1887. https://doi.org/10.1056/nejmoa1715275

  4. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. (Novel Start). N Engl J Med 2019;380(21):2020-2030. https://doi.org/10.1056/nejmoa1901963

  5. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007;62(6):591-604. https://doi.org/10.1111/j.1398-9995.2007.01394.x

  6. Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open 2017;7(9):e016688. https://doi.org/10.1136/bmjopen-2017-016688

  7. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149(3 Pt 1):604-610. https://doi.org/10.1164/ajrccm.149.3.8118625

  8. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med 2000;94(8):767-771. https://doi.org/10.1053/rmed.2000.0820




2020     |     www.medigraphic.com